| Chemotherapy-induced peripheral neurotoxicity (CIPN): an update AA Argyriou, J Bruna, P Marmiroli, G Cavaletti Critical reviews in oncology/hematology 82 (1), 51-77, 2012 | 647 | 2012 |
| Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature AA Argyriou, G Iconomou, HP Kalofonos Blood, The Journal of the American Society of Hematology 112 (5), 1593-1599, 2008 | 525 | 2008 |
| A review on oxaliplatin-induced peripheral nerve damage AA Argyriou, P Polychronopoulos, G Iconomou, E Chroni, HP Kalofonos Cancer treatment reviews 34 (4), 368-377, 2008 | 394 | 2008 |
| The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings G Cavaletti, DR Cornblath, ISJ Merkies, TJ Postma, E Rossi, B Frigeni, ... Annals of Oncology 24 (2), 454-462, 2013 | 344 | 2013 |
| Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature AA Argyriou, AP Kyritsis, T Makatsoris, HP Kalofonos Cancer management and research, 135-147, 2014 | 319 | 2014 |
| Peripheral nerve damage associated with administration of taxanes in patients with cancer AA Argyriou, M Koltzenburg, P Polychronopoulos, S Papapetropoulos, ... Critical reviews in oncology/hematology 66 (3), 218-228, 2008 | 317 | 2008 |
| Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial AA Argyriou, E Chroni, A Koutras, J Ellul, S Papapetropoulos, G Katsoulas, ... Neurology 64 (1), 26-31, 2005 | 303 | 2005 |
| Financial crisis and austerity measures in Greece: their impact on health promotion policies and public health care AA Ifanti, AA Argyriou, FH Kalofonou, HP Kalofonos Health policy 113 (1-2), 8-12, 2013 | 299 | 2013 |
| Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer AA Argyriou, G Cavaletti, C Briani, R Velasco, J Bruna, M Campagnolo, ... Cancer 119 (2), 438-444, 2013 | 261 | 2013 |
| Either called “chemobrain” or “chemofog,” the long-term chemotherapy-induced cognitive decline in cancer survivors is real AA Argyriou, K Assimakopoulos, G Iconomou, F Giannakopoulou, ... Journal of pain and symptom management 41 (1), 126-139, 2011 | 257 | 2011 |
| Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin P Alberti, E Rossi, DR Cornblath, ISJ Merkies, TJ Postma, B Frigeni, ... Annals of oncology 25 (1), 257-264, 2014 | 174 | 2014 |
| Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients R Velasco, J Bruna, C Briani, AA Argyriou, G Cavaletti, P Alberti, B Frigeni, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (4), 392-398, 2014 | 168 | 2014 |
| A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, ... Supportive Care in Cancer 14, 1134-1140, 2006 | 164 | 2006 |
| Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, ... Journal of pain and symptom management 32 (3), 237-244, 2006 | 162 | 2006 |
| Voltage‐gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin‐induced peripheral neurotoxicity: Results from a prospective multicenter study AA Argyriou, G Cavaletti, A Antonacopoulou, AA Genazzani, C Briani, ... Cancer 119 (19), 3570-3577, 2013 | 130 | 2013 |
| Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients AA Argyriou, R Velasco, C Briani, G Cavaletti, J Bruna, P Alberti, ... Annals of oncology 23 (12), 3116-3122, 2012 | 122 | 2012 |
| Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy AA Argyriou, E Chroni, P Polychronopoulos, G Iconomou, A Koutras, ... Neurology 67 (12), 2253-2255, 2006 | 115 | 2006 |
| Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial J Bruna, S Videla, AA Argyriou, R Velasco, J Villoria, C Santos, C Nadal, ... Neurotherapeutics 15 (1), 178-189, 2018 | 114 | 2018 |
| Physicians’ brain drain in Greece: a perspective on the reasons why and how to address it AA Ifanti, AA Argyriou, FH Kalofonou, HP Kalofonos Health Policy 117 (2), 210-215, 2014 | 112 | 2014 |
| The effect of depression on motor function and disease severity of Parkinson's disease S Papapetropoulos, J Ellul, AA Argyriou, E Chroni, NP Lekka Clinical neurology and neurosurgery 108 (5), 465-469, 2006 | 107 | 2006 |
